IP Library Granted Patent US 7,943,586
Granted Patent B2
US 7,943,586 · App. 10/560,075 · Granted May 17, 2011

Antineoplastic agents targeted via glut transporters

Assignee: The Trustees of the University of Pennsylvania
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,943,586
App. No.
10/560,075
Granted
May 17, 2011
Kind
B2
Abstract

The present invention relates to novel antineoplastic agents and cancer diagnostic agents that specifically target neo-plastic cells via the GLUT transportation system. More specifically, the invention relates to conjugates of 2-deoxyglucose, wherein a linker, which includes a covalent bond, is attached to 2-deoxyglucose at the 2 position, and the linker is attached to a therapeutic or diagnostic agent. The invention also relates to methods of treating tumor disease and methods of making the novel compounds of the present invention. The agents of the present invention are superior to previous agents as they are targeted via GLUT transporters.

Claims (7)

1. A 2-deoxyglucose conjugate, wherein said conjugate is represented by the formula:

or a pharmaceutically acceptable salt thereof, wherein L is a linker group;

and D is selected from the group consisting of BChlPP of the formula

BChlE6 (bacteriochlorin e 6 ) of the formula

and NIR664(tricarbocyanine) of the formula

2. The conjugate of claim 1 , wherein said linker group, L, is selected from the group consisting of a covalent bond, —NH—, -peptide-, -nucleic acid-, —O—, (CH 2 ) r —O—, —NH—CH 2 —CH 2 —NH—, —NH—CH(COOH)—CH 2 —NH—, —NH—CH 2 —CH(COOH)—NH—, —NH—CH 2 —CH 2 —CH 2 —NH, —O—(CH 2 ) r NH—, S—(CH 2 ) r —NH—, —S—(CH 2 ) r —C(O)—, —NH—CH 2 —C(O)—, —O-—CH 2 —CH 2 —O—CH 2 —CH 2 —O, —NH—NH—C(O)—CH 2 —, —NH—C(CH 2 ) 2 —C(O)—, and —NH—NH—C(O)—(CH 2 ) r —C(O)NH—N=., wherein r, in each instance, is from 2-5.

3. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.

Assignments (1)
CONFIRMATORY LICENSE Recorded Mar 14, 2013
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029993/0107 →
Continuity (5)
Provisional Application 60476648 · Jun 9, 2003
Provisional Application 60537282 · Jan 16, 2004
Provisional Application 60540700 · Jan 30, 2004
Provisional Application 60548240 · Feb 27, 2004
Related Publication 20060171893A1 · Aug 3, 2006